Basel Medical Group Ltd Ordinary Shares(BMGL)Earnings, Financials & Key Ratios
BMGL•NASDAQ•Insurance & Managed Care
Price updated Jun 24, 2026
AboutBasel Medical Group Ltd provides healthcare services. The company offers services in the areas of medical specialists, medical supplies and equipment, medical technology, and pharmaceuticals. The company was incorporated in 2023 and is based in Singapore.Show more
- Revenue$11M+12.6%
- Combined Ratio119.28%+52.6%
- Net Income-$12M-683.2%
- Return on Equity-194.55%-712.5%
- Medical Cost Ratio22.32%-0.2%
- Operating Margin-19.28%-188.3%
- Net Margin-106.78%-617.8%
- ROA-72.9%-657.2%
- Equity / Assets28.86%-37.8%
BMGL Key Insights
Basel Medical Group Ltd Ordinary Shares (BMGL) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Low loss ratio of 22.3%
✗Weaknesses
- ✗Unprofitable underwriting: 119.3% combined ratio
- ✗Shares diluted 15.6% in last year
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BMGL posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMGL Price & Volume
Basel Medical Group Ltd Ordinary Shares (BMGL) stock price & volume — 10-year historical chart
Loading chart...
BMGL Growth Metrics
Basel Medical Group Ltd Ordinary Shares (BMGL) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years2.03%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-
Return on Capital
10 Years10.75%
5 Years10.75%
3 Years5.79%
Last Year-28.52%
BMGL Peer Comparison
Basel Medical Group Ltd Ordinary Shares (BMGL) competitors in Healthcare Providers (Non-Insurers) — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ACMR | 6.73B | 101.60 | 74.16 | 15.24% | 9.48% | 5.13% | 0.16 | |
 CLOV | 2.7B | 5.21 | -30.65 | 40.34% | -2.58% | -17.08% | ||
 HCAI | 8.25M | 7.33 | -0.20 | -83.94% | -262.32% | 0.01 | ||
 SGBX | 32.96K | 0.96 | -0.00 | -69.88% | -5.69% | -134.41% | ||
 MD | 2.01B | 24.22 | 12.48 | -4.92% | 9.02% | 20.09% | 0.76 | |
 AMSF | 610.08M | 32.46 | 13.14 | 2.63% | 14.27% | 9.68% | 0.00 | |
 PRVA | 3.09B | 24.51 | 136.17 | 22.26% | 0.97% | 0.01% | 0.01 | |
 ALHC | 4.43B | 21.69 | -5862.16 | 46.06% | 0.47% | 11.5% | 1.89 |
Compare BMGL vs Peers
Basel Medical Group Ltd Ordinary Shares (BMGL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMGL Income Statement
Basel Medical Group Ltd Ordinary Shares (BMGL) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Revenue | 10.66M | 9.7M | 10.05M | 11.32M |
Revenue Growth % | - | -8.98% | 3.6% | 12.63% |
Medical Costs & Claims | 2.18M | 2.34M | 2.25M | 2.53M |
Medical Cost Ratio % | 20.44% | 24.09% | 22.37% | 22.32% |
Gross Profit | 8.48M▲ 0% | 7.36M▼ 13.1% | 7.8M▲ 5.9% | 8.79M▲ 12.7% |
Gross Margin % | 79.56% | 75.91% | 77.63% | 77.68% |
Gross Profit Growth % | - | -13.15% | 5.95% | 12.7% |
Operating Expenses | 6.01M | 5.36M | 5.61M | 10.98M |
OpEx / Revenue % | 56.34% | 55.27% | 55.79% | 96.97% |
Depreciation & Amortization | 575.92K | 557.13K | 528.73K | 1.18M |
Combined Ratio % | 76.79% | 79.36% | 78.16% | 119.28% |
Operating Income | 2.47M▲ 0% | 2M▼ 19.0% | 2.2M▲ 9.6% | -2.18M▼ 199.4% |
Operating Margin % | 23.21% | 20.64% | 21.84% | -19.28% |
Operating Income Growth % | - | -19.05% | 9.6% | -199.45% |
EBITDA | 3.05M | 2.56M | 2.72M | -1M |
EBITDA Margin % | 28.62% | 26.39% | 27.1% | -8.85% |
Interest Expense | 320.87K | 238.6K | 176.24K | 203.95K |
Non-Operating Income | -233.12K | -367.25K | -385.69K | 10.12M |
Pretax Income | 2.39M▲ 0% | 2.13M▼ 10.7% | 2.4M▲ 12.8% | -12.51M▼ 620.1% |
Pretax Margin % | 22.39% | 21.97% | 23.92% | -110.47% |
Income Tax | 408.48K | 348.28K | 331.76K | -417.39K |
Effective Tax Rate % | 17.12% | 16.34% | 13.8% | 3.34% |
Net Income | 1.98M▲ 0% | 1.78M▼ 9.8% | 2.07M▲ 16.2% | -12.09M▼ 683.2% |
Net Margin % | 18.56% | 18.38% | 20.62% | -106.78% |
Net Income Growth % | - | -9.84% | 16.23% | -683.15% |
EPS (Diluted) | 1.07▲ 0% | 0.96▼ 10.2% | 1.14▲ 17.7% | -5.16▼ 554.5% |
EPS Growth % | - | -10.17% | 17.66% | -554.55% |
EPS (Basic) | 1.07 | 0.96 | 1.14 | -5.16 |
Diluted Shares Outstanding | 1.35M | 1.35M | 1.35M | 1.57M |
BMGL Balance Sheet
Basel Medical Group Ltd Ordinary Shares (BMGL) balance sheet — assets, liabilities & shareholders' equity
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Total Assets | 16.85M | 15.38M | 16.31M | 16.85M |
Asset Growth % | - | -8.71% | 6.03% | 3.35% |
Total Investment Assets | 0 | 0 | 0 | 49 |
Long-Term Investments | 0 | 0 | 0 | 49 |
Short-Term Investments | 0 | 0 | 0 | 0 |
Total Current Assets | 15.67M | 14.77M | 16.17M | 13.12M |
Cash & Equivalents | 1.56M | 1.22M | 1.95M | 2.98M |
Receivables | 13.88M | 13.33M | 12.44M | 2.49M |
Other Current Assets | 0 | 0 | 1.59M | 31.8K |
Goodwill & Intangibles | 0 | 0 | 0 | 0 |
Goodwill | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 |
PP&E (Net) | 1.18M | 578.78K | 57.97K | 3.45M |
Other Assets | 0 | 0 | 0 | 0 |
Total Liabilities | 13.14M | 9.89M | 8.75M | 11.99M |
Total Debt | 10.15M | 7.21M | 4.29M | 3.42M |
Net Debt | 8.59M | 6M | 2.34M | 440.39K |
Long-Term Debt | 5.31M | 3.4M | 1.58M | 0 |
Short-Term Debt | 3.63M | 3.22M | 2.68M | 61.37K |
Total Current Liabilities | 7.19M | 6.47M | 7.16M | 10.69M |
Accounts Payable | 1.08M | 1.46M | 829.32K | 2.1M |
Deferred Revenue | 0 | 0 | 0 | 0 |
Other Current Liabilities | 405.5K | 490.73K | 458.31K | 15K |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Liabilities | 0 | 0 | 0 | 0 |
Total Equity | 3.71M▲ 0% | 5.49M▲ 48.1% | 7.56M▲ 37.8% | 4.86M▼ 35.7% |
Equity Growth % | - | 48.12% | 37.76% | -35.67% |
Shareholders Equity | 3.71M | 5.49M | 7.56M | 4.86M |
Minority Interest | 0 | 0 | 0 | 3.5K |
Retained Earnings | 3.71M | 5.49M | 7.56M | -4.4M |
Common Stock | 8 | 8 | 24.46M | 34.21M |
Accumulated OCI | 0 | 0 | -24.46M | -24.95M |
Return on Equity (ROE) | 53.38% | 38.79% | 31.77% | -194.55% |
Return on Assets (ROA) | 11.74% | 11.07% | 13.08% | -72.9% |
Equity / Assets | 21.99% | 35.69% | 46.37% | 28.86% |
Debt / Equity | 2.74x | 1.31x | 0.57x | 0.70x |
Book Value per Share | 2.74 | 4.05 | 5.58 | 3.11 |
Tangible BV per Share | 2.74 | 4.05 | 5.58 | 3.11 |
BMGL Cash Flow Statement
Basel Medical Group Ltd Ordinary Shares (BMGL) cash flow — operating, investing & free cash flow history
| Metric | Jun'22 | Jun'23 | Jun'24 | Jun'25 |
|---|---|---|---|---|
Cash from Operations | 2.79M | 2.6M | 2.51M | -4.34M |
Operating CF Growth % | - | -6.89% | -3.49% | -273.12% |
Operating CF / Revenue % | 26.2% | 26.8% | 24.97% | -38.38% |
Net Income | 2.39M | 2.13M | 2.4M | -12.51M |
Depreciation & Amortization | 575.92K | 557.13K | 528.73K | 1.18M |
Stock-Based Compensation | 0 | 0 | 0 | 0 |
Deferred Taxes | 0 | 0 | 0 | 0 |
Other Non-Cash Items | -251.26K | -375.51K | -419.19K | 10.23M |
Working Capital Changes | 81.37K | 286.8K | -4.82K | -3.25M |
Cash from Investing | -88.5K | -6.16K | -7.92K | -11.04M |
Capital Expenditures | -88.5K | -6.16K | -7.92K | -54.76K |
Acquisitions | 0 | 0 | 0 | -10.99M |
Purchase of Investments | 0 | 0 | 0 | 0 |
Sale/Maturity of Investments | 0 | 0 | 0 | 0 |
Other Investing | 0 | 0 | 0 | 0 |
Cash from Financing | -12.92M | -2.94M | -1.77M | 16.91M |
Dividends Paid | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 |
Stock Issued | 0 | 0 | 0 | 9.75M |
Debt Issuance (Net) | -1000K | -1000K | -1000K | -1000K |
Other Financing | -10.86M | 325 | 1.16M | 12.34M |
Net Change in Cash | -10.22M▲ 0% | -346.24K▲ 96.6% | 733.61K▲ 311.9% | 1.03M▲ 40.1% |
Exchange Rate Effect | 0 | 0 | 0 | -495.74K |
Cash at Beginning | 11.78M | 1.56M | 1.22M | 1.95M |
Cash at End | 1.56M | 1.22M | 1.95M | 2.98M |
Free Cash Flow | 2.7M▲ 0% | 2.59M▼ 4.1% | 2.5M▼ 3.6% | -4.4M▼ 275.9% |
FCF Growth % | - | -4.07% | -3.56% | -275.86% |
FCF Margin % | 25.37% | 26.74% | 24.89% | -38.86% |
FCF per Share | 2 | 1.92 | 1.85 | -2.81 |
BMGL Key Ratios
Basel Medical Group Ltd Ordinary Shares (BMGL) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|
Combined Ratio | 76.79% | 79.36% | 78.16% | 119.28% |
Medical Cost Ratio | 20.44% | 24.09% | 22.37% | 22.32% |
Return on Equity (ROE) | 53.38% | 38.79% | 31.77% | -194.55% |
Return on Assets (ROA) | 11.74% | 11.07% | 13.08% | -72.9% |
Equity / Assets | 21.99% | 35.69% | 46.37% | 28.86% |
Book Value / Share | 2.74 | 4.05 | 5.58 | 3.11 |
Debt / Equity | 2.74x | 1.31x | 0.57x | 0.70x |
Revenue Growth | - | -8.98% | 3.6% | 12.63% |
Related:BMGL Dividend History·BMGL Revenue History·BMGL Price History·BMGL P/E History·BMGL Financial Ratios·BMGL Institutional Holders
BMGL Frequently Asked Questions
Basel Medical Group Ltd Ordinary Shares (BMGL) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Basel Medical Group Ltd Ordinary Shares (BMGL) grew revenue by 12.6% over the past year. This is steady growth.
Basel Medical Group Ltd Ordinary Shares (BMGL) reported a net loss of $12.1M for fiscal year 2024.
Dividend & Returns
Basel Medical Group Ltd Ordinary Shares (BMGL) has a return on equity (ROE) of -194.6%. Negative ROE indicates the company is unprofitable.
Industry Metrics
Basel Medical Group Ltd Ordinary Shares (BMGL) has a combined ratio of 119.3%. A ratio above 100% means claims and expenses exceed premiums.